TRV GP V, LLC

CIK 1990717 · View on SEC EDGAR ↗

Portfolio value
$498.2M
#3,776 of 9,443 by 13F value · top 40.0%
Positions
3
As of
June 30, 2026

Portfolio value QoQ: +24.2% 13F does not disclose cash

Top 10 holdings weight
100.00%
Top 25 holdings weight
100.00%
Positions above 1%
3
Effective number of positions
2.2

Based on 13F long-equity holdings only (cash, bonds, shorts not disclosed)

Turnover Q2 2026: 0.0% Est. buys $0 · sells $35,615,682

Median holding: 6.5 quarters Tracked Q4 2024–Q2 2026 · 75.0% still held

New positions
0
Increased
0
Decreased
1
Closed
1
On this page

Performance vs S&P 500

Tracked Q4 2024–Q2 2026
+80.9%
S&P 500 total return (same window)
+28.1%
Excess return
+52.8%

Annualized: +48.6% · S&P 500: +18.0%

Approximates a buy-and-hold portfolio built from quarterly SEC 13F snapshots. Excludes cash, short positions, options/derivatives, and non-13(f) securities — reflects the disclosed long-equity book only, not total fund AUM. SEC filing lag is up to 45 days; this is not a real-time-copyable timing.

Priceable coverage: 97.8% · Options excluded: 0.0%

Sector breakdown

Healthcare
100.0%

Full portfolio 3 positions

Type Streak 8Q trend
RAPP Rapport Therapeutics, Inc. - Common Stock $261,709,477 52.53% 6,280,525 $38,448,036 Down ×1
SEPN Septerna, Inc. - Common Stock $208,160,143 41.78% 6,215,591 $58,799,491
MAZE Maze Therapeutics, Inc. - Common Stock $28,371,872 5.69% 950,800 $-9,508

Top movers (QoQ)

Security Action Shares Δ Value Δ
SEPN Price move only +0 +$58.8M
RAPP Trimmed -855K +$38.4M
MAZE Price move only +0 -$10K

Exited positions

Includes corporate events (mergers, delistings) — not all exits are sells

Closed positions reflect 13F reporting changes; for index managers these are often mechanical (delisting, M&A, index rebalancing), not active decisions.

SecurityQuarter Shares before Value before Price since exit
CRGX Sept. 30, 2025 1,737,216 $7,157,330 No longer tracked